NK520
/ Base Therap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 07, 2024
Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1 | N=9 | Recruiting | Sponsor: Base Therapeutics (Shanghai) Co., Ltd.
New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics
August 07, 2024
Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1 | N=9 | Recruiting | Sponsor: Base Therapeutics (Shanghai) Co., Ltd.
New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology
1 to 2
Of
2
Go to page
1